Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
about
Intelligent design: combination therapy with oncolytic virusesEvaluation of adenovirus capsid labeling versus transgene expressionImmunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma.The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabineArmoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis.In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cellsmiR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.The Werner syndrome protein functions in repair of Cr(VI)-induced replication-associated DNA damage.Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.Real-time monitoring of cisplatin cytotoxicity on three-dimensional spheroid tumor cells.Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway.Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivoMonitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time.Nuclear targeting peptide-modified, DOX-loaded, PHBV nanoparticles enhance drug efficacy by targeting to Saos-2 cell nuclear membranes.
P2860
Q24628227-7E6C6EC5-B26C-4E2C-9BF7-AAD1ECBB5527Q33669272-1E5DEFCF-9AE6-4E31-B78C-D9CF9960D9FDQ33713042-DB567FED-1AB8-45F7-B91B-321F7F837E65Q34238784-35CA0C75-D8FC-44F0-A97B-CC85350C7CC9Q34612613-6E63A2E3-4E69-4BF4-B33B-A65ECF84CF38Q34992785-FE09A4ED-A111-417E-BB6D-AC4D50C4F912Q35242640-F8BFBD2B-FA65-4C29-87D9-EBA1393374ECQ35545752-69A026AE-8045-41AE-8D2E-213A5EF3413FQ35591447-56ABBBD1-CA1D-46E3-824E-CF7960FB0125Q37256608-603B2A68-C961-4241-AC01-1675A46DC53FQ37867584-9B398FB8-EF03-4344-A1A0-5B29518D6F85Q38756515-A40FDC77-E79D-42E4-8673-49C772B62D5AQ38841629-102960E3-58A1-48C8-9544-B60C92283803Q39003657-6819BE4F-4214-4E78-B260-106A2C92C1FDQ39020219-C3813A8B-10E3-48A1-8D26-DFF0031FD357Q39310354-EA850E69-AD7B-4EFF-966E-09E9AD350D34Q39572504-708BFD7B-0C8A-429D-83E8-789B8027729EQ39782062-526340CA-65B4-4A07-BE7B-4C184BBD209AQ41788182-E36CAD14-875E-40A6-B646-DA97BC20B125Q47202732-F92DDB39-8F27-4A74-8DF9-3346245D6DC8
P2860
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Different susceptibility of os ...... and doxorubicin or cisplatin.
@en
type
label
Different susceptibility of os ...... and doxorubicin or cisplatin.
@en
prefLabel
Different susceptibility of os ...... and doxorubicin or cisplatin.
@en
P2093
P2860
P356
P1476
Different susceptibility of os ...... and doxorubicin or cisplatin.
@en
P2093
Gerritsen WR
Kaspers GJ
Schagen FH
Wuisman PI
van Beusechem VW
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603189
P407
P577
2006-05-30T00:00:00Z